Cognition Therapeutics(CGTX)
icon
搜索文档
Cognition Therapeutics(CGTX) - 2021 Q4 - Earnings Call Transcript
2022-03-30 21:19
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Q4 2021 Earnings Call March 30, 2022 8:00 AM ET Company Participants Daniel Kontoh-Boateng - Investor Relations Lisa Ricciardi - President and Chief Executive Officer Jim O'Brien - Chief Financial Officer Tony Caggiano - Chief Medical Officer and Head of R&D Conference Call Participants Mayank Mamtani - B. Riley Securities Disclaimer*: This transcript is designed to be used alongside the freely available audio recording on this page. Timestamps within the transcrip ...
Cognition Therapeutics(CGTX) - 2021 Q4 - Annual Report
2022-03-30 00:00
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period From To Commission file number: 001-40886 COGNITION THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 13-4365359 (State of Other ...
Cognition Therapeutics(CGTX) - 2021 Q3 - Quarterly Report
2021-11-17 00:00
Table of Contents 2500 Westchester Ave. Purchase, NY 10577 (Address of Principal Executive Offices) (412) 481-2210 (Registrant's telephone number) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Comm ...